Our Research

Discover our recent findings, catch up with news, and review in-depth resources.

Pharmacokinetics (PK) Urine Analysis

Whereas blood is collected for analysis at a discrete time point, urine is collected over periods of time known as collection intervals…

Challenges of Developing an ADA Assay for Bispecific Antibody Therapeutics and ADA Characterization

Bispecifics (Bs) are biopharmaceutical products that bind to two different targets (epitopes). These are mainly two types: IgG-like (antibodies Abs) and non-IgG-like which include Bites (bispecific T-cell engager) and DARTs (Dual-affinity Re-targeting Antibody)…

What Makes a Good LC-MS/MS Bioassay?

Liquid chromatography linked to tandem mass spectrometry (LC–MS/MS, LC-MS) is the “go-to” method for pharmacokinetics and metabolism studies across drug development with recent advances in separation, throughput and methods for analyzing protein biotherapeutics…

Beyond the Abstract: An Interview with Ashley Phillips

In this Bioanalysis Zone podcast episode, our Senior Scientist and Technical Specialist Ashley Phillips discusses his recent publication…

A Step-by-Step Guide to Developing a Robust Assay in Bioanalysis Using LC-MS/MS

LC-MS/MS assay development within Bioanalysis is driven by developing accurate, precise and robust methods within the shortest time frame possible…

8 Essential Characteristics of LC-MS/MS Method Validation

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a powerful technique in the field of bioanalysis, and it plays a critical role in drug development and clinical trials…
Scroll to Top

One Year On… ICH Q3D Guidelines Revision

It’s been over a year since the ICH Q3D guidelines were updated to include cutaneous and transcutaneous limits.

This crucial change allows the evaluation of topical products with risk-appropriate permitted daily exposures, rather than adopting more stringent parenteral limits.

Topical products, ranging from complex multicomponent patches and wound dressings to creams containing inorganic salts and polymers, require a tailored approach to sample preparation and analysis to ensure all the elements of concern are quantitatively determined.

To ensure comprehensive digestion and achieve the low limits of detection needed for these often high-dose materials, we’ve leveraged our extensive experience in elemental impurities analysis by developing bespoke digestion regimes, utilising HF if required.

For insights into ICH Q3D and its implementation, read the EMA guidelines.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now CEO at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.